Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library
- 1 April 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 317 (2), 515-521
- https://doi.org/10.1016/j.bbrc.2004.03.074
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Endoglin (CD105): a target for anti-angiogenetic cancer therapy.Current Drug Targets, 2003
- Strategies for vascular targeting in tumorsInternational Journal of Cancer, 2002
- Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer developmentSurgery, 2002
- Tumor angiogenesis as a therapeutic targetDrug Discovery Today, 2001
- Targeting of Adenovirus to Endothelial Cells by a Bispecific Single-Chain Diabody Directed against the Adenovirus Fiber Knob Domain and Human Endoglin (CD105)Molecular Therapy, 2001
- WAM: an improved algorithm for modelling antibodies on the WEBProtein Engineering, Design and Selection, 2000
- Antibody humanization: a case of the ‘Emperor’s new clothes’?Immunology Today, 2000
- Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides 1 1Edited by I. A. WilsonJournal of Molecular Biology, 2000
- Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using125I-labeled anti-endoglin monoclonal antibodiesInternational Journal of Cancer, 1999
- Elevated expression of endoglin, a component of the TGF-?-receptor complex, correlates with proliferation of tumor endothelial cellsInternational Journal of Cancer, 1999